Can you trust what you hear? Concurrent misinformation affects recall memory and judgments of guilt.

n most misinformation studies, participants are exposed to a to-be-remembered event, and then subsequently given misinformation in textual form. This misinformation impacts on people’s ability to accurately report the initial event. In this paper, we present two experiments that explored a different approach to presenting misinformation. In the context of a murder suspect, the to-be-remembered event was audio of a police interview, whilst the misinformation was co-presented as subtitles with some words being different to, and more incriminating than, those that were actually said. We refer to this as concurrent misinformation. In Experiment 1, concurrent misinformation was inappropriately reported in a cued-recall test, and inflated participants’ ratings of how incriminating the audio was. Experiment 2 attempted to employ warnings to mitigate the influence of concurrent misinformation. Warnings after the to-be-remembered event had no effect, whilst warnings before the event reduced the effect of concurrent misinformation for a sub-set of participants. Participants that noticed the discrepancy between the audio and the sub-titles were also less likely to judge the audio as incriminating. These results were considered in relation to existing theories underlying the misinformation effect, as well as the implication for the use of audio and text in applied contexts

Effects of Foliar Fertilization and Fungicide Applications on Yield and Grade of Peanuts (Arachis Hypogaea L.)

Agronom

The Effect of Software Team Personality Composition on Learning and Performance: Making the Dream Team

Optimizing work team composition in organizational and educational environments is an important task toward maximizing performance. Social science research has revealed that personality trait composition influences team cohesion and performance. However, this research has not been well-adapted into the IS context. In addition, prior research demonstrates how individual personality traits impact teams, but fails to appropriately characterize overall team personality composition. We expand this research by 1) characterizing holistic personality compositions, and 2) examining team learning in addition to performance in the IS context. We draw from theory on team performance and Big 5 trait composition. Results demonstrate that teams comprised of homogenous versus heterogeneous personality compositions differ in their performance and learning. The primary implication of this research is that teams can benefit from a priori personality measurements and directed composition. Initially, optimal learning and effectiveness comes from homogenous teams. However, this may change over time

A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia

Objectives: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent cure rates and minimal side effects. Despite the high burden of disease, strategies to ultimately eradicate HCV are being developed. However, the delivery of care in regional settings is challenging and the efficacy of decentralised models of care is incompletely defined. Methods: A prospective cohort study of patients whose treatment was initiated or supervised by Cairns Hospital, a tertiary hospital which provides services to a culturally diverse population across a 380,748 km2 area in regional Australia. Patients` demographics, clinical features, DAA regimens and outcomes were recorded and correlated with their ensuing clinical course. Results: Over 22 months, 734 patients were prescribed DAA therapy for HCV. No patients were prescribed interferon. Sofosbuvir/ledipasvir (n=371, 50.5%) and sofosbuvir/daclatasvir (n=287, 39.1%) were the most commonly prescribed regimens. No patients ceased treatment due to adverse effects. There were 612/734 (83.4%) patients with complete results, with 575 (94%) cured. At the end of the study period, there were 50 (6.8%) patients lost to follow-up and 72 (9.8%) awaiting SVR12 testing. The presence of cirrhosis (n=147/612, 24.1%) did not impact significantly on SVR12 rates, this being achieved in 136/147 (92.5%) cirrhotic patients versus 440/465 (94.6%) in non-cirrhotic patients (p=0.34). Treatment-experienced patients (95/612, 18.3%) were more likely to be non-responders than treatment-naive patients (10/95 (10.5%) versus 26/517 (5%), p=0.04). Strategies to facilitate treatment included a dedicated clinical nurse consultant, education to primary health care providers, specialist outreach clinics to regional communities and shared care with general practitioners. SVR12 rates were similar amongst gastroenterologists (283/306, 92.5%), general practitioners (152/161, 94.4%), sexual health physicians (104/106, 98.1%) and other prescribers (37/39, 94.9%). Conclusions: This study confirms that decentralised, multidisciplinary models of care can provide HCV treatment in regional and remote settings with excellent outcomes

Adjuvants for Leishmania vaccines: from models to clinical application

Two million new cases of leishmaniasis occur every year, with the cutaneous leishmaniasis (CL) presentation accounting for approximately two-thirds of all cases. Despite the high incidence rates and geographic expansion of the disease, CL remains a neglected tropical disease without effective intervention strategies. Efforts to address this deficit have given rise to the experimental murine model of CL. By virtue of its simplicity and pliability, the CL model has been used to provide substantial information regarding cellular immunity, as well as in the discovery and evaluation of various vaccine adjuvants. The CL model has facilitated in vivo studies of the mechanism of action of many adjuvants, including the TLR4 agonist monophosphoryl lipid A, the TLR7/8 agonist imiquimod, the TLR9 agonist CpG, adenoviral vectors, and the immunostimulatory complexes. Together, these studies have helped to unveil the requirement for certain types of immune responses at specific stages of CL disease and provide a basis to aid the design of effective second-generation vaccines for human CL. This review focuses on adjuvants that have been tested in experimental CL, outlining how they have helped advance our understanding of the disease and ultimately, how they have performed when applied within clinical trials against human CL